SBH
ACAD icon

Segall Bryant & Hamill’s Acadia Pharmaceuticals ACAD Stock Holding History

Segall Bryant & Hamill’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
53,034
-67,987
-56% -$1.5M 0.02% 514
2026
Q1 		$2.69M Sell
121,021
-5,045
-4% -$121K 0.04% 384
2025
Q4 		$3.37M Buy
+126,066
New +$3.01M 0.05% 364

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Segall Bryant & Hamill's ACAD Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its Acadia Pharmaceuticals (ACAD) stake by 56% in Q2 2026, selling an estimated $1.5M and leaving 53,034 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #514.

Segall Bryant & Hamill first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.37M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Segall Bryant & Hamill held 53,034 shares of Acadia Pharmaceuticals worth $1.34M as of Q2 2026.
  • Segall Bryant & Hamill sold 67,987 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.5M.
  • Acadia Pharmaceuticals made up 0.02% of Segall Bryant & Hamill's portfolio in Q2 2026, its #514 holding.
  • Segall Bryant & Hamill first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Segall Bryant & Hamill's Acadia Pharmaceuticals position peaked at $3.37M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.